Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

k-RAS mutation and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer.

Journal of cancer research and therapeutics - 1 Jan 2017

Zhou Bin, Tang Congrong, Li Jie

Abstract excerpt

OBJECTIVE: The aim of this study was to evaluate the relationship between k-RAS gene mutation and the resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with nonsmall-cell lung cancer (NSCLC). METHODS: Forty-five pathologies confirmed NSCLC patients who received EGFR-TKI (Gefitinib) treatment were retrospectively included in this study. The mutation of codon...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinazolines

Source

Identifiers

PMID: 28901317
DOI: 10.4103/jcrt.JCRT_468_17

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

k-RAS mutation and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer.PMID 28901317Read ↗

[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].Semantic proximity Read ↗

[K-RAS gene mutations in patients with non-small cell lung cancer].Semantic proximity Read ↗

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.Semantic proximity Read ↗

Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma.Semantic proximity Read ↗

[Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer].Semantic proximity Read ↗

Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

Across the universe of K-RAS mutations in non-small-cell-lung cancer.Semantic proximity Read ↗

Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.Semantic proximity Read ↗

The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.Semantic proximity Read ↗

[Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].Semantic proximity Read ↗

Potential Clinical Significance of a Plasma-Based <i>KRAS</i> Mutation Analysis in Patients with Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.